Treatment of TNBC
Individualizing Care for Patients With Triple-Negative Breast Cancer

Released: January 18, 2023

Expiration: January 17, 2024

Mark D. Pegram
Mark D. Pegram, MD
Sara M. Tolaney
Sara M. Tolaney, MD, MPH

Activity

Progress
1
Course Completed

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:

  • Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC
  • Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC
  • Current data and treatment strategies and the future of antibodydrug conjugates in the management of relapsed/refractory advanced TNBC
  • Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBC
  • Role of PARP inhibitors in the treatment of TNBC